Practice Management

 View Only
  • 1.  Lung Cancer Screening in IDTF Setting

    Posted 02-11-2022 10:49
    CMS has announced very exciting news regarding the expansion of lung cancer screening CT imaging within the IDTF setting.  Teh big news is that CMS has acted to remove barriers to IDTFs receiving referralsa and performing these LDCT lung cancer screening studies.  CMS noted, "While smoking cessation services are appropriate for patiens, we are not making it a requirement that imaging facilities furnish the service because it would prevent IDTFs from furnishing LDCT screening."

    RBMA has worked for many years within a coalition of organizations to change this National Coverage Determination to expand LDCT screening within the IDTF setting.  I recall a meeting 4 years ago with CMS officials where I asked a CMS medical director, "Wouldn't it feel great to go home this evening and tell your family you potentially are saving smokers from cancer?"  While the CMS official didn't seem to appreciate the question they now can do this.  

    Here is the complete CMS statement:  

    https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=304



    ------------------------------
    Robert Still FRBMA
    Executive Director
    Radiology Business Management Association (RBMA)
    Fairfax VA
    (703) 621-3363
    ------------------------------



  • 2.  RE: Lung Cancer Screening in IDTF Setting

    Posted 02-11-2022 11:30

    This is indeed great news! Sharing by blog post on the NCD with more details.

     

    https://viewpoints.reedsmith.com/post/102himu/cms-seeks-to-improve-access-to-lung-cancer-screenings-in-revised-national-coverag

     

     

    Thomas W. Greeson

    703.517.0495 (cell)

    tgreeson@reedsmith.com

    Pronouns: He/Him/His

     

    Reed Smith LLP

    7900 Tysons One Place

    Suite 500

    McLean, Virginia 22102-5979

    Office: 703 641 4242

    Cell:     703.517.0495

    Facsimile:   703 641 4340

     

     

     

     






  • 3.  RE: Lung Cancer Screening in IDTF Setting

    Posted 02-11-2022 14:30

    Been waiting for this since March 2021!  I however did not see an effective date in the communication from CMS nor has there been anything posted by our MAC.  Am I missing something?

     

    Ruby O'Brochta-Woodward BSN, CPC, CDEO, CPMA, CPB, CPC-I, COSC, CSFAC, RCC

    Coding Supervisor| Consulting Radiologists, Ltd.

    7505 Metro Blvd. | Suite 400 | Edina, MN | 55439

    Phone:  612.573.2223 | Fax:  612.573.2250

    ruby.obrochtawoodward@crlmed.com

    www.consultingradiologists.com


    Notice:  [CONFIDENTIALITY AND PRIVACY NOTICE] Information transmitted by this email is proprietary to Consulting Radiologists, Ltd.  and is intended for use only by the individual or entity to which it is addressed, and may contain information that is private, privileged, confidential or exempt from disclosure under applicable law. If you are not the intended recipient or it appears that this mail has been forwarded to you without proper authority, you are notified that any use or dissemination of this information in any manner is strictly prohibited. In such cases, please delete this mail from your records.

     






  • 4.  RE: Lung Cancer Screening in IDTF Setting

    Posted 02-15-2022 15:06

    You didn't miss it, I can't find an effective date in any document I've read.  Does anyone have an idea?

     

    John

     






  • 5.  RE: Lung Cancer Screening in IDTF Setting

    Posted 02-15-2022 15:15

    Under Section VIII in the NCD, see this comment and response.

     

    Comment:  One commenter asked when the changes are effective.

    Response:  All NCDs are effective on the date the final decision memoranda are posted.

     

    The revised NCD was posted on February 10, 2022.

     

    Thomas W. Greeson

    703.517.0495 (cell)

    tgreeson@reedsmith.com

    Pronouns: He/Him/His

     

    Reed Smith LLP

    7900 Tysons One Place

    Suite 500

    McLean, Virginia 22102-5979

    Office: 703 641 4242

    Cell:     703.517.0495

    Facsimile:   703 641 4340

     

     

     

     






  • 6.  RE: Lung Cancer Screening in IDTF Setting

    Posted 02-15-2022 15:50

    Thanks, Tom.  Great article by your firm, too.

     

    John

     






  • 7.  RE: Lung Cancer Screening in IDTF Setting

    Posted 02-16-2022 07:16

    Still nothing on our MACs site either.

     

    Ruby O'Brochta-Woodward BSN, CPC, CDEO, CPMA, CPB, CPC-I, COSC, CSFAC, RCC

    Coding Supervisor| Consulting Radiologists, Ltd.

    7505 Metro Blvd. | Suite 400 | Edina, MN | 55439

    Phone:  612.573.2223 | Fax:  612.573.2250

    ruby.obrochtawoodward@crlmed.com

    www.consultingradiologists.com


    Notice:  [CONFIDENTIALITY AND PRIVACY NOTICE] Information transmitted by this email is proprietary to Consulting Radiologists, Ltd.  and is intended for use only by the individual or entity to which it is addressed, and may contain information that is private, privileged, confidential or exempt from disclosure under applicable law. If you are not the intended recipient or it appears that this mail has been forwarded to you without proper authority, you are notified that any use or dissemination of this information in any manner is strictly prohibited. In such cases, please delete this mail from your records.

     






  • 8.  RE: Lung Cancer Screening in IDTF Setting

    Posted 02-16-2022 09:15

    As Tom Greeson replied yesterday, it is effective on February 10, 2022, the day the decision memo was posted.

     






  • 9.  RE: Lung Cancer Screening in IDTF Setting

    Posted 02-16-2022 10:09

    Thank, John.

     

    I have added the date the NCD became effective to my blog article describing the new NCD.

     

    https://viewpoints.reedsmith.com/post/102himu/cms-seeks-to-improve-access-to-lung-cancer-screenings-in-revised-national-coverag

     

    Thomas W. Greeson

    703.517.0495 (cell)

    tgreeson@reedsmith.com

    Pronouns: He/Him/His

     

    Reed Smith LLP

    7900 Tysons One Place

    Suite 500

    McLean, Virginia 22102-5979

    Office: 703 641 4242

    Cell:     703.517.0495

    Facsimile:   703 641 4340